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Introduction
Reprogramming of metabolism is a recognized hallmark of cancer (1) , with altered fluxes in both anabolic and catabolic pathways. Recent work has shown, for example, that some breast cancers are dependent upon increased serine biosynthesis (2) and that human lung tumors show high levels of both glycolysis and glucose oxidation (3) . Tumors often preferentially reduce pyruvate to lactate, rather than oxidize it in the tricarboxylic acid (TCA) cycle. This failure to oxidize pyruvate, even in the presence of oxygen (the "Warburg Effect"), is not because mitochondria in cancer cells are necessarily dysfunctional, but rather because flux of pyruvate carbon into the TCA cycle is down regulated (4) . A major function of the TCA cycle in tumors is to generate building blocks for macromolecular biosynthesis, such as acetyl-CoA for fatty acid synthesis and amino acids for protein synthesis. As in other tissues, tumors can utilize fuels other than glucose for energy generation, such as glutamine, fatty acids, ketone bodies and amino acids, with tumors adapting to nutrient availability and other micro-environmental factors (4) . Tumor cells can also exist in a metabolic symbiosis, whereby hypoxic tumor cells import glucose and export lactate, while nearby normoxic cells import and catabolize this lactate (5) .
Altered metabolic fluxes in cancer cells are intimately linked to control of redox state.
NADPH, which maintains a major cellular anti-oxidant, glutathione, in a reduced state, can be generated by flux of glutamine carbon through the TCA cycle to malate, with the production of NAPDH in the reaction catalyzed by NADP+-dependent malic enzyme (ME, EC 1.1.1.40), and by flux of glucose carbon into the pentose phosphate pathway (PPP) (4) . Decreased glycolytic flux resulting from oxidation of a sensitive sulfhydryl residue in the pyruvate kinase (PK) isoform PKM2, promotes diversion of glucose carbon into the PPP (6) . Flux is also diverted into the PPP by TP53-induced glycolysis and apoptosis regulator (TIGAR), which possesses fructose 2,6-bisphosphatase activity, and re-routes glycolytic flux into the PPP by decreasing the amount of fructose 2,6-bisphosphate, a potent allosteric activator of the glycolytic enzyme phosphofructokinase 1 (PFK1) (7) . Flux of serine and glycine carbon through the tetrahydrofolate (THF) pathway also generates NADPH (2) . Increased uptake of glucose and glutamine by cancer cells drives the hexosamine pathway, which yields metabolites involved in protein and lipid glycosylation. Increased O-glycosylation of proteins with N-acetylglucosamine promotes cancer cell metabolic reprogramming and cell survival and sialylation of cell-surface carbohydrates is associated with increased metastasis (8).
The differences in metabolism between tumors and normal tissues and the changes in tumor metabolism during disease progression and in response to treatment make metabolic imaging techniques important tools for detecting and grading tumors and for guiding therapy in individual patients (9) (see Figure 1 and Table 1 ).
PET
Positron Emission Tomography (PET) with the glucose analogue, 2-[
18 F]fluoro-2-deoxy-Dglucose (FDG) is the most widely used metabolic imaging technique in the clinic for tumor staging and assessment of treatment response (10) . FDG is trapped by phosphorylation in the reaction catalyzed by the first enzyme in the glycolytic pathway, hexokinase. Many tumor cells overexpress the glucose transporters (GLUT) 1 and 3 and therefore take up large amounts of FDG. However, FDG-PET suffers from a lack of specificity as increased glucose uptake also occurs in inflammation (11) . Moreover, sensitivity is low in tumors with a low glycolytic rate, such as prostate tumors, or where the tumors are located in a tissue with high glucose uptake, such as the brain (9) . The Royal College of Radiologist's guidelines recommend that imaging tumor treatment response with FDG-PET should commence weeks to months after chemo-or radiotherapy (12) , which hampers rapid assessment of a therapy's effectiveness. Recently, a PET tracer for imaging PKM2 expression has been described, 11 C]DASA-23, which may be more useful for detecting the increased aerobic glycolytic activity of tumors than FDG. The tracer showed clear delineation of implanted patientderived glioblastoma tumors in mouse brain (13 A drawback of PET is that only tracer uptake can be assessed, although this may be related to underlying metabolism. Information on true metabolic conversion requires blood sampling to obtain dynamic information on metabolite formation (21). This is not a problem for magnetic resonance spectroscopy (MRS) since the spectrum can identify the observed molecule. For example, glycolytic flux cannot be assessed from PET measurements of FDG uptake, which is rather an indication of glucose uptake than glycolytic flux to pyruvate and lactate. In a study of canine tumors undergoing sequential imaging with hyperpolarized [1- However, low spatial resolution and long acquisition times would make these 13 C MRS measurements in vivo challenging to use in a routine clinical setting. 31 P MRS was used in an early study of a human tumor in situ (34) , however a lack of sensitivity has inhibited its use in clinical oncology. The 19 F nucleus is almost as sensitive as the proton to NMR detection and has the advantage that there is no background signal in biological systems. 19 F MRS has been used mainly for tracking labeled cells (35) and for detecting probes sensitive to various biologically relevant parameters, such as tumor hypoxia (36) . A recent advance is the use of combined PET/MR scanners (37) . For example, simultaneous diffusion-weighted MRI and PET measurements of 18 F-FDG uptake in both preclinical models and patients (38, 39) allowed metabolic effects to be distinguished from changes in cell viability. However, in the case of glucoCEST, the contributions of intracellular glucose, glucose metabolites and glucose in the vasculature and interstitial space to the signal are currently unknown.
CEST

Dynamic Nuclear Polarization
Signal from injected 13 C-labelled metabolites can be increased greatly (>10 
Imaging cell surface glycosylation
Cell surface glycosylation is important for cell-cell communication and adhesion, and hypersialylation of cell surface glycans confers metastatic potential to a range of cancer cells (8) .
Glycosylation can be imaged using appropriately labeled probes that bind specific glycan moieties (63). However, probe-based techniques give only a static picture of cell surface glycosylation, whereas metabolic labeling can give information on glycan turnover. Cell surface glycans can be metabolically labeled with unnatural azido-sugars and the incorporated sugars can then be reacted in vivo with bioorthogonal probes (64), and visualized, for example, with fluorescence imaging (65), MRI (66) or radionuclide imaging (67) . Further development of sensitive radionuclide-labeled probes may allow high contrast real-time metabolic imaging of cancer glycosylation in vivo, which in the longer term has the potential to be translated to the clinic, where it could be used to image cancer progression and assess metastatic potential.
The future of metabolic imaging in oncology
There are some aspects of tumor metabolism for which there is as yet no imaging probe.
Metabolic pathways important for both proliferation and resistance to oxidative stress, such as the PPP and the THF pathway, which produce NADPH, are underexplored imaging targets.
Enzymes involved in serine synthesis are emerging drug targets (68) and an imaging technique that could visualize serine/glycine metabolism and one-carbon transfer in vivo could improve our understanding of this branch of metabolism. Hyperpolarized [U-2 H, U- Combining different imaging modalities such as PET/MR (37) with DNP (22) will increase the information content of the imaging examination, allowing more specific information to be obtained from the relatively few metabolic imaging tracers that have been approved for clinical use (70) . A newly emerging health concern in the clinic is the potential toxicity of gadolinium contrast media used in MRI (71) . In principle some of the roles of these contrast media could be replaced with hyperpolarized 13 C-labeled cell substrates, for example hyperpolarized 13 C urea, which has been used to assess tissue perfusion (72) . The power of metabolic imaging with hyperpolarized 13 C-labeled cell substrates is that it gives information on dynamic processes. However, its weakness is that there is no information on the pathway. Glutamine is deamidated by glutaminase (GLS), which can yield NADPH via NADP+-dependent malic enzyme (ME, EC 1. localised spectra, where the surface coil was placed directly over the heart/liver region (58) . 
